Rishi Kumar Gara, Vasudha Sundram, Subhash C. Chauhan and Meena Jaggi Pages 4177 - 4184 ( 8 )
Ormeloxifene is a non-steroidal Selective Estrogen Receptor Modulator (SERM) that is used as an oral contraceptive. Recent studies have shown its potent anti-cancer activities in breast, head and neck, and chronic myeloid leukemia cells. Several in vivo and clinical studies have reported that ormeloxifene possesses an excellent therapeutic index and has been well-tolerated, without any haematological, biochemical or histopathological toxicity, even with chronic administration. A reasonably long period of time and an enormous financial commitment are required to develop a lead compound into a clinically approved anti-cancer drug. For these reasons and to circumvent these obstacles, ormeloxifene is a promising candidate on a fast track for the development or repurposing established drugs as anti-cancer agents for cancer treatment. The current review summarizes recent findings on ormeloxifene as an anti-cancer agent and future prospects of this clinically safe pharmacophore.
Breast cancer, cancer, chemo-resistance, chronic myeloid leukemia, contraceptive, head and neck squamous cell carcinoma, ormeloxifene, ovarian cancer, prostate cancer, SERM.
, , , 2301 East 60<sup>th</sup> Street North, Sioux Falls, SD 57104-0589.